Explore our featured news items here. Subscribe to stay informed of all information shared and published by OHC.

Sponsor appreciation:

You’re invited to explore and join Physician Factor, a knowledge exchange network is a dedicated portal for physicians seeking opportunities to contribute their expertise and input in exchange for compensation and supplemental income.

You can search articles using your own keywords or the following tags: Lung Cancer | Breast Cancer | Drugs and Therapies | Cancer General

November is Lung Cancer Awareness Month: Join the AACR in Advancing Research for Prevention and Treatment
OHC Editor OHC Editor

November is Lung Cancer Awareness Month: Join the AACR in Advancing Research for Prevention and Treatment

November is Lung Cancer Awareness Month, highlighting the urgent need for research and action to prevent and treat lung cancer, the leading cause of cancer death in the United States. The AACR is actively supporting groundbreaking research and advocating for policies to reduce smoking-related cancers and improve outcomes for those diagnosed with the disease.

Read More
Emerging Use of Weight Loss Drugs in Cancer Treatment
OHC Editor OHC Editor

Emerging Use of Weight Loss Drugs in Cancer Treatment

Recent interest suggests that these antiobesity drugs could play a role in cancer care. Although data supporting the use of GLP-1 agonists for weight loss in cancer patients is limited, some oncologists are beginning to explore their application and study their effects.

Read More
A New Targeted Treatment Shows Promise for Select Patients with Stomach Cancer
OHC Editor OHC Editor

A New Targeted Treatment Shows Promise for Select Patients with Stomach Cancer

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and New York-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker. If approved, zolbetuximab will be the first targeted therapy in the U.S. for patients with previously untreated advanced gastric or esophageal junction cancer that is human epidermal growth factor receptor 2 (HER2)-negative and overexpresses the protein claudin-18 isoform 2 (CLDN 18.2).

Read More
AI Model Could Help Improve Outcomes Of Prostate Cancer Focal Therapy
OHC Editor OHC Editor

AI Model Could Help Improve Outcomes Of Prostate Cancer Focal Therapy

Scientists at UCLA developed an AI model that helps determine how extensive cancer is within the prostate gland. In a series of tests, the AI model was found to be more accurate at predicting tumor margins than magnetic resonance imaging (MRI), potentially improving the effectiveness of focal therapy, standardizing treatment margin definition, and reducing the chance of cancer recurrence.

Read More
PD-1/CTLA-4 Combination Drives Progress Across Tumor Types
OHC Editor OHC Editor

PD-1/CTLA-4 Combination Drives Progress Across Tumor Types

Immunotherapy has been unsuccessful in advanced solid tumors refractory to standard therapy, including PD-1 and CTLA-4, because of hostile tumor microenvironments. The tide has begun to change, however, with the advent of a novel combination that can penetrate cold and immunotherapy-refractory tumors.

Read More
Exercise As Medicine In The Treatment Of Cancer
OHC Editor OHC Editor

Exercise As Medicine In The Treatment Of Cancer

In 1996 there were four randomized controlled trials that had tested the effects of exercise on outcomes within people living with and beyond cancer. By 2010, there were 82 exercise and cancer trials. But by 2018, there were over 680 trials noted in the National Library of Medicine. As a result of that exponential increase in evidence, sixteen major medical associations came together in 2018 to review the evidence and develop exercise guidance.

Read More
First Test Of Anti-Cancer Agent PAC-1 In Human Clinical Trials Shows Promise
OHC Editor OHC Editor

First Test Of Anti-Cancer Agent PAC-1 In Human Clinical Trials Shows Promise

A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers. The drug stalled the growth of tumors in the five people in the trial with neuroendocrine cancers and reduced tumor size in two of those patients. It also showed some therapeutic activity against sarcomas, scientists and clinicians report in the British Journal of Cancer.

Read More
NCI Study Advances Personalized Immunotherapy For Metastatic Breast Cancer
OHC Editor OHC Editor

NCI Study Advances Personalized Immunotherapy For Metastatic Breast Cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research.

Read More
How Melanoma Prepares Lymph Nodes for Metastases
OHC Editor OHC Editor

How Melanoma Prepares Lymph Nodes for Metastases

Melanoma cells release small extracellular packages containing the protein nerve growth factor receptor (NGFR), which primes nearby lymph nodes for tumor metastases, according to a new study by Weill Cornell Medicine investigators.

Read More